R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

From pilots to patients: Why the UK must rethink NHS innovat...

At PharmaTech Integrates in Glasgow, speakers from government, academia, the NHS, and pharma sought to define the sector’s path forward.

R&D

pharmaphorum podcast Episode 207a, Brandon Pence

The importance of being disruption ready, with Brandon Pence

Brandon Pence, recently appointed President and COO of Fujifilm Biosciences, discusses the cell culture media industry and being disruption ready.

R&D

Q3 Clinical trials round-up: July to September 2025

As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.

R&D

The hidden cost of rework in pharma facility builds

If a facility is late or non-compliant, the entire supply chain can be compromised, from R&D labs to hospital shelves.

R&D

Why conditions like UTI call for new antibiotics

Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.

R&D

Alzheimer’s research: Cutting through the noise to find the ...

A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.